Cost-effectiveness evaluation of benmelstobart, anlotinib and chemotherapy in patients with extensive-stage small-cell lung cancer
Triple therapy was a less cost-effective option for patients with ES-SCLC compared with anlotinib plus EC and EC alone in China.
Authors
- Jiyong Wu
- Siyu Dai
- Xu Zhao (ORCID: https://orcid.org/0000-0001-7015-6252)
- Changgui Kou (ORCID: https://orcid.org/0000-0001-9544-4066)
- Jing Nie (ORCID: https://orcid.org/0000-0001-5080-6553)
- Ke Tang
Institutions
- Linyi University (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-08-19
- DOI
- https://doi.org/10.3389/fphar.2025.1524108
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00